Papillary adenocarcinomas of the prostate. An immunohistochemical study

Kuhajda, Francis P.; Gipson, Thomas; Mendelsohn, Geoffrey

doi:10.1002/1097-0142(19841001)54:7<1328::aid-cncr2820540716>3.0.co;2-f

Cited by 14 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the first description of this tumour Melicow and Pachter 1 proposed that it arose from mü llerian remnants, thus explaining its morphological similarity to uterine endometrioid carcinoma. Positive immunostaining for PAP and PSA was first demonstrated by Kuhajda et al 8 . Subsequently, several authors have published series of collected cases 5,9-12 . Zaloudek et al 13 first questioned the oestrogen dependency of this lesion when a patient inadvertantly had an orchiectomy performed for endometrioid carcinoma, with subsequent tumour regression.…”

Section: Discussionmentioning

confidence: 89%

Ductal (endometrioid) adenocarcinoma of the prostate: a clinicopathological study of 16 cases

1996

View full text Add to dashboard Cite

Sixteen cases of ductal (endometrioid) carcinoma of the prostate are presented. The tumour presents in elderly men (age range 65-87 years) with haematuria or obstructive symptoms. Serum prostate specific antigen may be normal or raised. On cytoscopy, there is often an exophytic lesion in the region of the verumontanum. Histologically, two variants are recognized: papillary and cribriform, of which there were eight cases each. Eight cases consisted of pure ductal carcinoma and seven were mixed, containing a variable proportion of micro-acinar carcinoma. The associated micro-acinar carcinoma had a Gleason score of at least 5. One case of carcinosarcoma with a ductal epithelial component was also included. All cases displayed positive immunohistochemical staining for prostate specific antigen and prostatic acid phosphatase and but were negative for the basal cell marker MA903. The tumour responds well to orthodox micro-acinar carcinoma therapy and appears notably sensitive to hormonal manipulation. Follow-up of the mixed group is restricted to a maximum of 3 years. Of the eight pure cases, five patients are still alive with survival periods of 11, 8, 7, 3 and 1 years. Three patients died of intercurrent disease of which one patient survived 12 years, having received no treatment. This tumour, therefore, can be regarded as having a good prognosis.

show abstract

Section: Discussionmentioning

confidence: 89%

Ductal (endometrioid) adenocarcinoma of the prostate: a clinicopathological study of 16 cases

1996

View full text Add to dashboard Cite

show abstract

“…It was thought that papillary formations or complex glands would not develop within the peripheral zone (PZ) due to limited space and stromal formation. 13 It has now been shown that DAC may also involve the PZ, 4,5,40 and that this may even be the most common location for these tumours. 38 The Gleason grading system is one of the most powerful predictive factors in prostate cancer.…”

Section: Histopathologymentioning

confidence: 99%

Ductal adenocarcinoma of the prostate: histogenesis, biology and clinicopathological features

et al. 2016

View full text Add to dashboard Cite

“…Papillary carcinoma of the prostate is an uncommon neoplasm. Since Melicow and Pachter [l] first described this tumor in 1967, only 128 such tumors have been reported, either as "endometrial" or endometrioid carcinomas, or carcinomas of prostatic ducts [1][2][3][4][5][6][7][8][9][10][11][12][16][17][18][19][20]. These tumors are located characteristically in the region of the verumontanum and exhibit urethroscopically discernible papillary configurations.…”

Section: Introductionmentioning

confidence: 99%

Papillary carcinoma of the prostate, location, morphology, and immunohistochemistry: The histogenesis and entity of so‐called endometrioid carcinoma

Wernert

Lüchtrath²,

Seeliger

et al. 1987

The Prostate

View full text Add to dashboard Cite

Fifty carcinomas that were partially to completely papillary in nature were examined. According to urethroscopic and rectal palpation findings, six of the carcinomas were located centrally, 40 tumors were in the prostate proper, and four were clinical stage T0. The epithelium of the papillary portions of the tumors was dark in some instances, light in others. Immunohistochemistry revealed that 20 of 22 tumors were positive for prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA). In no case was a topical relationship to the utriculus prostaticus demonstrable. The epithelium of the utriculus in seven additional patients who were not involved in this series also stained positively for PAP and PSA. Usual carcinomas of the prostate proper can develop endometrioid structures that do not differ immunohistochemically from ordinary portions of the carcinoma. Tumors located in central portions of the prostate are, in our opinion, morphologic variants of usual prostatic carcinomas, and apparently arise in prostatic ducts. We conclude that a distinction between endometrioid carcinomas and tumors of prostatic ducts does not seem justified and that papillary prostatic carcinomas should be treated like common prostatic cancer.

show abstract

Papillary adenocarcinomas of the prostate. An immunohistochemical study

Cited by 14 publications

References 10 publications

Ductal (endometrioid) adenocarcinoma of the prostate: a clinicopathological study of 16 cases

Ductal (endometrioid) adenocarcinoma of the prostate: a clinicopathological study of 16 cases

Ductal adenocarcinoma of the prostate: histogenesis, biology and clinicopathological features

Papillary carcinoma of the prostate, location, morphology, and immunohistochemistry: The histogenesis and entity of so‐called endometrioid carcinoma

Contact Info

Product

Resources

About